Despite high healthcare costs, nearly half of the patients did not achieve clear/nearly clear skin. These data, in the context of reducing costs for biosimilars, may provide a basis to challenge care pathways and access criteria for 'high-cost' treatments.
Gribaleva et al. (Fri,) studied this question.